

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 77773

**Title:** Therapies for Non-Alcoholic Fatty Liver Disease: A 2022 Update

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03538879

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Chief Doctor, Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2022-05-19

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-05-20 02:31

**Reviewer performed review:** 2022-05-22 04:46

**Review time:** 2 Days and 2 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements

Conflicts-of-Interest: [ ] Yes [Y] No

## SPECIFIC COMMENTS TO AUTHORS

The increasing epidemic of NAFLD has become a global public health problem. Clinicians and pharmaceutical companies all over the world are working together to deal with this challenge. Lifestyle modification is the basis for the treatment of NAFLD, which can effectively reduce hepatic and metabolic risks. However, lifestyle modification is suitable to all the patients, and the development of new drugs is in urgent need. In this paper, the authors reviewed the disease spectrum of NAFLD, the evaluation of NASH, and the understanding of the pathogenesis of insulin resistance, lipid metabolism and liver inflammation, as well as the currently recommended interventions, such as Mediterranean diet, FXR agonists, PPAR pan agonists, and the update research progress of these therapies. It is a well-prepared review article. Minor concerns Although gut microbiota and epigenetics are not drug important targets, they are critical mechanisms of NAFLD development and progression, which should be thoroughly discussed.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 77773

**Title:** Therapies for Non-Alcoholic Fatty Liver Disease: A 2022 Update

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05270042

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Assistant Professor

**Reviewer's Country/Territory:** Viet Nam

**Author's Country/Territory:** United States

**Manuscript submission date:** 2022-05-19

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-05-26 10:31

**Reviewer performed review:** 2022-06-01 10:01

**Review time:** 5 Days and 23 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [ ] Yes [Y] No

#### **SPECIFIC COMMENTS TO AUTHORS**

This is a very useful article on an important and common disease, and it gives hope to NAFLD patients. 1. Regarding NAFLD pathology, the author should specify the most important and common reasons. 2. On GLP-1 Receptor agonist and SGL T2 inhibitors, the author should clarify the previously done studies and indicate references. 3. In targeted lipid metabolism treatments, the author should indicate which drugs were the most promising for clinical application.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 77773

**Title:** Therapies for Non-Alcoholic Fatty Liver Disease: A 2022 Update

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05208113

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Assistant Professor, Lecturer

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2022-05-19

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-05-26 05:23

**Reviewer performed review:** 2022-06-03 09:26

**Review time:** 8 Days and 4 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements

Conflicts-of-Interest: [ ] Yes [Y] No

#### **SPECIFIC COMMENTS TO AUTHORS**

This review provided general knowledge about the spectrum of NAFLD, “multiple hits” pathophysiological theory, and current recommended interventions. Importantly it summarised the update on therapies under evaluation. For section about current or being evaluated interventions for NAFLD, it is better to distinguish simple steatosis and NASH. Moreover, could FXR agonists be classified as Therapies Targeting Insulin Resistance? After summary of interventions for NAFLD, authors should provide some prospective opinion for future therapies.